An Update on Select Topics in Chronic Rhinosinusitis With Nasal Polyps
DOI:
https://doi.org/10.58931/cait.2021.1320Abstract
Chronic rhinosinusitis affects approximately 5-15% of the population and has an economic burden estimated to be between $22 – $64.5 billion US dollars per year. The condition causes significant reductions in quality of life, productivity and emotional wellbeing for patients. Furthermore it is a top ten leading cause of employee absenteeism.
References
Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope. 2015 July;125(7):1547-56. doi:10.1002/lary.25180
Caulley L, Thavorn K, Rudmik L, et al. Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: Results of the US Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2015 Dec;136(6):1517-22. doi:10.1016/j.jaci.2015.08.037
Klonaris D, Doulaptsi M, Karatzanis A, et al. Assessing quality of life and burden of disease in chronic rhinosinusitis: a review. Rhinology Online. 2019 Aug;2:6-13.
Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015 Apr;152(2 Suppl):S1-S39. doi:10.1177/0194599815572097
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi:10.4193/Rhin20.600
McHugh T, Snidvongs K, Xie M, et al. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018 Dec;8(12):1421-9. doi:10.1002/alr.22194
Ho J, Hamizan AW, Alvarado R, et al. Systemic Predictors of Eosinophilic Chronic Rhinosinusitis. Am J Rhinol Allergy. 2018 Jul;32(4):252-7. doi:10.1177/1945892418779451
Ho J, Earls P, Harvey RJ. Systemic biomarkers of eosinophilic chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):23-29. doi:10.1097/ACI.0000000000000602
McHugh T, Snidvongs K, Xie M, et al. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018 Dec;8(12):1421-9. doi:10.1002/alr.22194
Seresirikachorn K, Kerr SJ, Aeumjaturapat S, et al. Predictive factors for identifying macrolide responder in treating chronic rhinosinusitis. Rhinology. 2021 Jun 1;59(3):284-291. doi: 10.4193/Rhin20.649
DelGaudio JM, Loftus PA, Hamizan AW, et al. Central compartment atopic disease. Am J Rhinol Allergy. 2017 Jul 1;31(4):228-34. doi:10.2500/ajra.2017.31.4443
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi:10.4193/Rhin20.600
Stevens WW, Peters AT, Tan BK, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2812-2820.e3. doi:10.1016/j.jaip.2019.05.009
Cao PP, Wang ZC, Schleimer RP, Liu Z. Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes. Ann Allergy Asthma Immunol. 2019 Jan;122(1):33-40. doi:10.1016/j.anai.2018.10.014
Philpott CM, Smith R, Davies-Husband CR, et al. Exploring the association between ingestion of foods with higher potential salicylate content and symptom exacerbation in chronic rhinosinusitis. Data from the National Chronic Rhinosinusitis Epidemiology Study. Rhinology. 2019 Aug;57(4):303-12. doi:10.4193/Rhin19.027
Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1061-70.e3. doi:10.1016/j.jaip.2016.12.027
Levy JM, Rudmik L, Peters AT, et al. Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2016 Dec;6(12):1273-83. doi:10.1002/alr.21826
Fruth K, Pogorzelski B, Schmidtmann I, et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68:659-65. doi:10.1111/all.12131
Grayson JW, Cavada M, Harvey RJ. Clinically relevant phenotypes in chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2019 May;48(1):23. doi:10.1186/s40463-019-0350-y
Younis RT, Anand VK, Davidson B. The role of computed tomography and magnetic resonance imaging in patients with sinusitis with complications. Laryngoscope. 2002 Feb;112(2):224-9. doi:10.1097/00005537-200202000-00005
Bhattacharyya N. A comparison of symptom scores and radiographic staging systems in chronic rhinosinusitis. Am J Rhinol. 2005 Mar-Apr;19(2):175-9.
Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997 Sep;117(3 Pt 2):S35-40. doi:10.1016/S0194-59989770005-6
Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009 Oct;34(5):447-54. doi:10.1111/j.1749-4486.2009.01995.x
Rudmik L, Soler ZM, Mace JC, et al. Using preoperative SNOT-22 score to inform patient decision for Endoscopic sinus surgery. Laryngoscope. 2015 Jul;125(7):1517-22. doi:10.1002/lary.25108
Rudmik L, Soler ZM, Hopkins C. Using postoperative SNOT-22 to help predict the probability of revision sinus surgery. Rhinology. 2016 Jun;54(2):111-6. doi:10.4193/Rhino15.284
Fokkens WJ, Lund VJ, Mullol J, Babchert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012 Mar;50(1):1-12. doi:10.4193/Rhino12.000
Masterson L, Tanweer F, Bueser T, Leong P. Extensive endoscopic sinus surgery: does this reduce the revision rate for nasal polyposis?. Eur Arch Otorhinolaryngol. 2010 Oct;267(10):1557-1561. doi:10.1007/s00405-010-1233-z
Harvey RJ, Goddard JC, Wise SK, Schlosser RJ. Effects of endoscopic sinus surgery and delivery device on cadaver sinus irrigation. Otolaryngol Head Neck Surg. 2008 Jul;139(1):137-42. doi:10.1016/j.otohns.2008.04.020
Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol.2017 Oct;140(4):1024-31.e14. doi:10.1016/j.jaci.2017.05.044
Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011 Nov;128:988-9. doi:10.1016/j.jaci.2011.07.056
Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006 Nov;118(5):1133-41. doi:10.1016/j.jaci.2006.05.031
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi:10.1016/j.jaci.2012.07.047
Tsetsos N, Goudakos JK, Daskalakis D, Konstantinidis I, Markou K. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018 Mar 1;56:11-21. doi:10.4193/Rhino17.156
Bachert C, Zinreich SJ, Hellings PW, Mullol J, Hamilos DL, Gevaert P, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020 Feb 1;58(1)10-17. doi:10.4193/Rhin18.282
Bachert C, Hellings PW, Mullol J, Hamilos D, Gevaert P, Naclerio RM, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020 Jan;75(1):148-157. doi:10.1111/all.13984
Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol.Pract 2019 Sep-Oct;7(7):2447-2449.e2. doi:10.1016/j.jaip.2019.03.023
Claim Secure Drug Review. DUPIXENT Breakthrough Treatment for Severe Atopic Dermatitis. Accessed May 26, 2021. Available from: https://www.claimsecure.com/en/drug-reviews-blog/2018/september/dupixent-drug-review/.
Scangas GA, Wu AW, Ting JY, et al. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2021 Jan;131(1):E26-e33. doi:10.1002/lary.28648
Thamboo A, Kilty S, Witterick I, Chan Y, Chin CJ, Janjua A, et al. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2021 Mar 9;50(1):15. doi:10.1186/s40463-021-00493-2